TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: increase in tandem step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in tandem step time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal ultrafiltration (UF) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative recurrence rate of HCC
Endpoint domain: Mortality/survival
Primary endpoint: Post-intervention FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: CI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Higher mean scores in adaptive tutorial groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Higher engagement reported by students
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall perceived value of adaptive tutorials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive long-term retention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of perioperative stroke
Endpoint domain: Mortality/survival
Primary endpoint: perioperative mortality within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Calcium Ion Concentration (Ca)(i)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total serum aluminium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrafiltrable aluminium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for caries removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASQ gross motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma MMA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time for hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of groin bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of groin hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: higher number of blocks moved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher percentage of blocks moved by the impaired hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster motor reaction time (peripheral component)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster total reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of asystole
Endpoint domain: Mortality/survival
Primary endpoint: Clinical remission or marked improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete miscarriage within 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Patellar tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical femorotibial angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congruence angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive subject-rated effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative subject-rated effects
Endpoint domain: Adverse events/effects
Primary endpoint: quit rates at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Tunica media-to-internal lumen ratio (M/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dose reduction due to hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Days alive and free from mechanical ventilation at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in weekly vomiting frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: maximum aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of S. haematobium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severe septic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Severe vascular side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Median platelet recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean TMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Elasticity Reduction (SER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Severity Level (CSL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: relative's behavioral problems
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: dysfunctional thoughts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal anemia at 36-38 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: VAP + VAT incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median length of MV before first episode of VAP or VAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of activated charcoal dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume during the first 1.0 second (FEV(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative incidence of second malignancies
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of immediate test ordering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time of stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence management cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weekly UI frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of target-vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FE(NO) measurement validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory control impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state concentrations of clarithromycin in ELF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state concentrations of clarithromycin in AM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state concentrations of 14-hydroxyclarithromycin in AM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-OH-D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: likelihood of safe drinking limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fraction of cured patients (euthyroid or hypothyroid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mammillary body volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of major abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of pfcrt T76 mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pfmdr 1 Y86 mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of chloroquine resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defined infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean changes in scores for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean changes in scores for anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cephalic version at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with sensory blockade in the femoral nerve distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak force variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month acute rejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 12-month graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 12-month patient survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Proximal antral motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Catheter-associated bacteremia or fungemia
Endpoint domain: Adverse events/effects
Primary endpoint: Colonization of catheters
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean daily F/V servings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma lutein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: s-25OHD concentrations > 30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: s-25OHD concentrations > 20 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: s-25OHD concentrations > 16 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median content of FeNO in exhaled air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of atrial fibrillation
Endpoint domain: Mortality/survival
Primary endpoint: Radiofrequency delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time taken on MIST-VR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: economy of movements on MIST-VR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on MIST-VR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of ventricular lead-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of NICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: physical activity participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microhardness values of dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to follow simple commands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fit for discharge from recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak urine antioxidant potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BMI z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse symptoms following chiropractic care
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter-related bloodstream infections (BSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sedation agitation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total CMS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FACT‐Bv4.0 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: TPBA-UTI
Endpoint domain: Adverse events/effects
Primary endpoint: severe TPBA-UTI
Endpoint domain: Adverse events/effects
Primary endpoint: University of Pennsylvania Smell Identification Test (UPSIT) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPSIT subscore for pleasant smells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional results in the KSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision of implants for early loosening or infection
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from arrhythmia recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant WHO grade >or=2 Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe WHO grade >or=3 Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Oral Mucositis Assessment Scale ulceration score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No longer taking prednisone at 76 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At least 1 flare-up by the end of follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Median prednisone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: speeded performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AHI index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical excitability modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of V5/MT-stimulated phosphene reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance on alcohol-related issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interactional skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complication frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Improved earplug use practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent changes in BMD at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean percent changes in BMD at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak high-frequency power fraction during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Galpha(i2) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social support level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of Zarzio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Zarzio
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of Zarzio
Endpoint domain: Adverse events/effects
Primary endpoint: Basal lipolysis in SAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of ABPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores on the Revised‐Neonatal Oral Motor Assessment nutritive suck scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dice score for segmentation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to segment one CT image
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: shortness of breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of PCO requiring Nd:YAG capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation of therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total monthly medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage drop in titre following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of maternal care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention in maternal care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma levels of Bb and SC5b-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total drug dose received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of uninterrupted analgesia (time to first rescue bolus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of supplementary injections required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Long-term stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: 3-year all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Control of edema at mandibular angle measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell activation (CD38 +/HLA-DR+ CD8 cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission rate (PCDAI score ≤10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in systemic and social quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Monocyte chemotactic activity (MCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptance of increased risk of recurrence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Student satisfaction with teaching sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of HAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immunological function (IgG and IL-6 levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Active affected wrist extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HRT use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Menopausal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximal velocity of transport (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficiency of transport (Ef)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Apparent affinity constant (Kt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Long-term memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change from baseline of EQ-5D utilities
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Septal wall (SW) thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage thickening ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative complications (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the curve from 0 to 12h (AUC(0‐12h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COP velocity in both directions of sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability deterioration when deprived of visual information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for extracorporeal membrane oxygenation
Endpoint domain: Adverse events/effects
Primary endpoint: Neurologically intact survival (Modified Rankin Score ≤ 3)
Endpoint domain: Mortality/survival